uniQure N.V.

Stage 3 · Topping · week 4

As of Oct 22, 2026, uniQure is in Stage 3, the topping phase, now in week 4 (since Sep 29, 2026). It closed at $23.11, 67.3% below its 52-week high and below its 200-day average, which is rising.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. More about the company

$23.11

+1.76% today

$1.6B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is QURE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 23w

S2 17w

S2 14w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 6w → S4 23w → S1 3w → S2 8w → S3 5w → S4 1w → S3 1w → S2 17w → S3 9w → S2 14w → S3 2w → S2 14w → S3 7w → S4 15w → S1 7w → S2 13w → S3 3w current

Total tracked: 166 weeks across 18 stage runs.

QURE among Biotechnology409th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…409	QUREuniQure N.V.	Stage 3 · wk 4	17	−46.0%

vs 52W High

-67.3%

$9.03 lo$70.59 hi

67.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-22.0%

200 DMA: $29.63 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.71x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-46.0%

-40.7%

+31.8%

YTD

-1.2%

-63.4%

Scan Membership

Breakout Watch

Latest: 2025-05-15

9 appearances in last 60 days. First seen: 2019-02-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 0.71x

2026-10-21S3

Wk 4 · Vol 0.41x

2026-10-20S3

Wk 4 · Vol 0.65x

2026-10-19S3

Wk 3 · Vol 0.62x

2026-10-16S3

Wk 3 · Vol 0.59x

2026-10-15S3

Wk 3 · Vol 0.74x

2026-10-14S3

Wk 3 · Vol 1.56x

2026-10-13S3

Wk 3 · Vol 1.18x

2026-10-12S3

Wk 2 · Vol 0.67x

2026-10-09S3

Wk 2 · Vol 0.97x

2026-10-08S3

Wk 2 · Vol 0.84x

2026-10-07S3

Wk 2 · Vol 0.82x

Moving averages & range

50 DMA

$37.46

200 DMA

$29.63

52W High

$70.59

52W Low

$9.03

5D Low

$21.78

Resistance levels (recent highs)

20d High

$39.11

60d High

$51.05

120d High

$51.05

250d High

$70.59

Next resistance

+69.2%

to 20d High

ROE

-157.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 4.9

uniQure: quick answers

What stage is uniQure in?

As of Oct 22, 2026, uniQure (QURE) is in Stage 3, the topping phase. It entered Stage 3 on Sep 29, 2026 and is in week 4. What the four stages mean

Is uniQure in an uptrend?

Its uptrend has stalled. uniQure is in Stage 3, the topping phase that follows an advance. It trades 22.0% below its 200-day average, which is rising.

How far is uniQure from its 52-week high?

uniQure closed at $23.11 on Oct 22, 2026, 67.3% below its 52-week high of $70.59. Its 52-week low is $9.03.

How has uniQure performed over the past year?

As of Oct 22, 2026, uniQure is down 63.4% over the past year and down 1.2% so far in 2026.

Which sector and industry is uniQure in?

uniQure is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.